During the month of June on this blog, I got annoyed not once, but twice. First, I got annoyed at Sharon Begley for a truly annoying and evidence-free (other than cherry-picked anecdotes) broadside against the NIH for its “culture of caution” that, according to her, is largely responsible for the “lack of progress” against cancer […]
Category: Clinical trials
Two of the major themes on this blog since the very beginning has been the application of science- and evidence-based medicine to the care of patients and why so much of so-called “complementary and alternative” medicine, as well as fringe movements like the anti-vaccine movement, have little or–more commonly–virtually no science to support their claims […]
Share this:
Last year, a seeming victory for the protection of human subjects from being subjected to pseudoscience. It began when Kimball C. Atwood IV, MD; Elizabeth Woeckner, AB, MA; Robert S. Baratz, MD, DDS, PhD; and Wallace I. Sampson, MD published a lengthy criticism of the NIH Trial to Assess Chelation Therapy (TACT) in Medscape, pointing […]
Share this:
This is just a brief followup to my post this morning about yesterday’s NYT article on cancer research. An excellent discussion of the NYT article can be found here (and is well worth reading in its entirety). In it, Jim Hu did something I should have done, namely check the CRISP database in addition to […]
Share this:
On Friday, I expressed my irritation at the misunderstanding of science by NEWSWEEK’s science columnist Sharon Begley, in which she opines that it is those nasty basic scientists who insist on learning new science and new physiological mechanisms of disease that are devaluing translational and clinical research, in effect ghettoizing them in low impact journals, […]
